The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / TNFi Exposure in Utero

TNFi Exposure in Utero

September 26, 2018 • By Arthritis & Rheumatology

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Background & objective: In North America, infections are the leading cause of mortality in children ages younger than 5 years old, accounting for over 30% of deaths. Tumor necrosis factor inhibitors (TNFi’s) are important drugs in the treatment of rheumatoid arthritis (RA), being used in one-third of patients. Because animal studies did not show fetal risk, TNFi’s have been commonly—and increasingly used—during pregnancy, now prescribed in 20% of RA pregnancies, representing a threefold increase over the past 10 years.

You Might Also Like
  • Prenatal TNF Inhibitor Exposure Not Linked to Serious Infections
  • TNF Blocking Drugs Persist in Infants after Exposure In-Utero
  • Paternal Methotrexate Exposure Not Tied to Adverse Pregnancy Outcomes

Despite existing concerns that these potent drugs may cause immunosuppression, data on the risk of serious infection in exposed offspring are limited. During pregnancy, active transplacental transport of maternal circulating immunoglobulins (IgG) through their Fc portion takes place. TNFi’s are all monoclonal IgG with an Fc part, except for etanercept and certolizumab, and most TNFi’s are actively transported across the placenta, with some reaching higher fetal than maternal blood levels.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Vinet et al. set out to evaluate the risk of serious infections in children of women with RA exposed to TNFi’s in the gestational period compared with unexposed offspring of women with RA, as well as to children from the general population.

Methods: These researchers used U.S. claim data (2011–2015) to identify 2,989 offspring born to women who have RA and a randomly selected group of 14,596 control children, matched ≥4:1 for maternal age, year of delivery and state of residence. The researchers defined TNFi exposure based on one or more filled prescriptions during pregnancy. They ascertained serious infections based on one or more hospitalizations, with infection as a primary diagnosis, at 12 months or younger. They performed multivariable analyses, adjusting for maternal demographics, comorbidities, pregnancy complications and drugs.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Results: Among RA offspring, 380 (12.7%) were exposed to TNFi’s during pregnancy. At 2%, the rate of serious infections in RA offspring with no TNFi exposure was similar to non-RA offspring (1.9%); the percentage of serious infections in RA offspring with TNFi exposure was 3.2%. In multivariable analyses, the researchers could not establish an increased risk of serious infections in RA offspring exposed to TNFi’s compared with unexposed offspring of women with RA or RA offspring unexposed to TNFi.

Conclusion: These researchers did not demonstrate a marked excess risk for serious infections in RA offspring exposed to TNFi’s during pregnancy when compared with unexposed offspring of women with RA or general population controls. However, they could not exclude a differential risk according to specific TNFi, with infliximab potentially resulting in a threefold increase in the risk of serious infections compared with other TNFi’s. More studies are needed to further evaluate if the risk of serious infections in exposed offspring is influenced by individual TNFi characteristics.

Pages: 1 2 | Single Page

Filed Under: DMARDs & Immunosuppressives, Drug Updates Tagged With: Arthritis & Rheumatology, infants, pregnancy, TNF inhibitors

You Might Also Like:
  • Prenatal TNF Inhibitor Exposure Not Linked to Serious Infections
  • TNF Blocking Drugs Persist in Infants after Exposure In-Utero
  • Paternal Methotrexate Exposure Not Tied to Adverse Pregnancy Outcomes
  • Study Supports Safety of Infliximab in Pregnancy

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.